US Upholds $70m Hospira Epogen Verdict
Biosimilar Safe Harbors Need Record Of Non-Commercial Use, Ruling Suggests
Federal Circuit affirms jury's $70m award to Amgen and finding that some Hospira biosimilar batches were not protected by the safe harbor. Decision conveys how biosimilar makers can obtain this protection from infringement suits.
You may also be interested in...
Hospira Will Not Be Reheard On Retacrit Biosimilar
Hospira has been frustrated again in long-running litigation concerning its Retacrit biosimilar to Amgen’s Epogen, in a case closely watched by the biopharma industry as it addressed what constitutes a safe harbor for a biosimilar applicant.
Pfizer’s Retacrit undercuts rivals
Pfizer has launched its Retacrit (epoetin alfa-epbx) biosimilar in the US – the first US biosimilar rival to the Procrit and Epogen epoetin alfa brands for treating anaemia – at a price that undercuts these versions by around three-fifths and more than a third respectively. Highlighting the “substantial discount” represented by Retacrit’s wholesale acquisition cost (WAC) of US$11.03 per 1,000 units/ml, Pfizer noted that this was 57.1% below US$25.72 for Procrit and 33.5% less than US$16.58 for Epogen. Pfizer has a US marketing tie-up with Vifor for Retacrit “in certain channels”.
Hospira is hit for US$80mn
Pfizer’s Hospira will have to pay Amgen more than US$80 million in damages over an infringed US patent protecting Epogen (epoetin alfa). A final judgement issued by Delaware District Judge Richard Andrews awarded the originator pre-judgement interest of just over US$10.0 million on top of the US$70 million damages granted by a jury last year. In addition, Hospira will have to pay post-judgement interest calculated at the statutory rate of 1.31%.